Sun Yao, Zhao Huiying, Yang Shuguang, Wang Guangjie, Zhu Leijie, Sun Chang, An Youzhong
Department of Critical Care Medicine, Peking University People's Hospital, PR China.
Heliyon. 2024 Mar 10;10(6):e27306. doi: 10.1016/j.heliyon.2024.e27306. eCollection 2024 Mar 30.
Currently, stem cells are a prominent focus of regenerative engineering research. However, due to the limitations of commonly used stem cell sources, their application in therapy is often restricted to the experimental stage and constrained by ethical considerations. In contrast, urine-derived stem cells (USCs) offer promising advantages for clinical trials and applications. The noninvasive nature of the collection process allows for repeated retrieval within a short period, making it a more feasible option. Moreover, studies have shown that USCs have a protective effect on organs, promoting vascular regeneration, inhibiting oxidative stress, and reducing inflammation in various acute and chronic organ dysfunctions. The application of USCs has also been enhanced by advancements in biomaterials technology, enabling better targeting and controlled release capabilities. This review aims to summarize the current state of research on USCs, providing insights for future applications in basic and clinical settings.
目前，干细胞是再生工程研究的一个突出重点。然而，由于常用干细胞来源的局限性，它们在治疗中的应用往往仅限于实验阶段，并受到伦理考量的限制。相比之下，尿液衍生干细胞（USCs）在临床试验和应用方面具有显著优势。采集过程的非侵入性使得能够在短时间内重复获取，使其成为更可行的选择。此外，研究表明，USCs对器官具有保护作用，可促进血管再生、抑制氧化应激，并减轻各种急慢性器官功能障碍中的炎症。生物材料技术的进步也推动了USCs的应用，实现了更好的靶向性和控释能力。本综述旨在总结USCs的当前研究状况，为其在基础和临床环境中的未来应用提供见解。
